US FDA issues EIR for Lupin’s injectable facility in Nagpur
Lupin receives Establishment Inspection Report for injectable unit following US FDA inspection in June 2024
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Nilesh Gupta
Lupin receives US FDA Establishment Inspection Report for Somerset facility
The inspection, conducted in January 2025, confirms compliance standards at Lupin’s New Jersey manufacturing site
The quest for quality continues
It is considerably more difficult to live up to these professed codes of conduct off stage, as it needs to flow right from the…
9th Advanced GMP Workshop 2024 was organised by IPA
The workshop was attended by over 2,500 professionals including CXOs of the pharma industry, academia, and leaders from WHO,…
IPA organises eighth Advanced GMP Workshop
The workshop aimed to facilitate sharing of knowledge and the development of capabilities among Indian pharma companies,…
Lupin signs MoU with Maha Govt to combat cardiovascular diseases and COPD
Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services
US FDA accepts biologics license application from Lupin for pegfilgrastim biosimilar
This BLA expands the company's oncology portfolio
US FDA issues two observations after inspection of Lupin’s Pithampur unit
The inspection was carried out between February 3 and February 11, 2020
Lupin said the US health regulator has issued two…
Lupin Q3 net loss widens to Rs 835 cr
Consolidated sales of the company stood at Rs 3,716 crore
Lupin reported widening of its consolidated net loss to Rs 835 crore…
Lupin’s Pithampur facilities complete successful MHRA inspection
The inspection of the three units at Pithampur closed with no critical observation and one major observation, the pharma major…